Affinity Asset Advisors, LLC
- SEC CIK
- 0001773195
- Latest filing
- Aug 13, 2026
Holdings in Q4 2021
Holdings as of Dec 31, 2021, filed Feb 11, 2022. Long positions only; changes compare share counts with Q3 2021.
- Positions
- 46
- −20 vs. Q3 2021
- Portfolio value
- $234.4M
- −$16.8M (−6.7%) vs. Q3 2021
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| MORFMorphic Holding, Inc. | COM | 399,302 | $18.9M | 8.1% | +128,547+47.5% | Added | History |
| SWTXSpringWorks Therapeutics, Inc. | COM | 298,545 | $18.5M | 7.9% | +172,532+136.9% | Added | History |
| VINCVincerx Pharma, Inc. | COM NEW | 1,135,365 | $11.6M | 4.9% | +130,365+13.0% | Added | History |
| NARIInari Medical, Inc. | Stock | 125,000 | $11.4M | 4.9% | −10,000−7.4% | Reduced | History |
| ZNTLZentalis Pharmaceuticals, Inc. | COM | 117,500 | $9.88M | 4.2% | +40,000+51.6% | Added | History |
| ARNAArena Pharmaceuticals Inc | COM NEW | 100,000 | $9.29M | 4.0% | +100,000 | New | History |
| KDNYChinook Therapeutics, Inc. | COM | 555,155 | $9.05M | 3.9% | +480,814+646.8% | Added | History |
| PTGXProtagonist Therapeutics, Inc | COM | 241,119 | $8.25M | 3.5% | +241,119 | New | History |
| BBIOBridgeBio Pharma, Inc. | COM | 494,046 | $8.24M | 3.5% | −160,389−24.5% | Reduced | History |
| KURAKura Oncology, Inc. | COM | 560,000 | $7.84M | 3.3% | +30,000+5.7% | Added | History |
| Retrophin Inc761299AB2 | NOTE 2.500% 9/1 | – | $7.73M | 3.3% | – | – | – |
| CERECerevel Therapeutics Holdings, Inc. | COM | 225,000 | $7.29M | 3.1% | −34,966−13.5% | Reduced | History |
| ARYEARYA Sciences Acquisition Corp V | CLASS A ORD SHS | 702,500 | $6.81M | 2.9% | 00.0% | Unchanged | History |
| CYTKCytokinetics Inc | COM NEW | 145,552 | $6.63M | 2.8% | +20,552+16.4% | Added | History |
| ACRSAclaris Therapeutics, Inc. | COM | 400,000 | $5.82M | 2.5% | +50,000+14.3% | Added | History |
| RPTXRepare Therapeutics Inc. | COM | 271,778 | $5.73M | 2.4% | +271,778 | New | History |
| BridgeBio Pharma, Inc.10806XAB8 | NOTE 2.500% 3/1 | – | $5.53M | 2.4% | – | New | – |
| MDGLMadrigal Pharmaceuticals, Inc. | COM | 65,000 | $5.51M | 2.3% | +65,000 | New | History |
| NAUTNautilus Biotechnology, Inc. | COM | 1,049,721 | $5.44M | 2.3% | +74,721+7.7% | Added | History |
| ESTAEstablishment Labs Holdings Inc. | COM | 77,500 | $5.24M | 2.2% | +17,500+29.2% | Added | History |
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 419,144 | $4.72M | 2.0% | +215,961+106.3% | Added | History |
| XENEXenon Pharmaceuticals Inc. | COM | 150,500 | $4.70M | 2.0% | +100,500+201.0% | Added | History |
| Bellus Health Inc New07987C204 | COM NEW | 500,000 | $4.03M | 1.7% | −32,030−6.0% | Reduced | – |
| ARYDARYA Sciences Acquisition Corp IV | CL A | 400,000 | $3.97M | 1.7% | −200,000−33.3% | Reduced | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 100,000 | $3.86M | 1.6% | +59,846+149.0% | Added | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 175,000 | $3.83M | 1.6% | +175,000 | New | History |
| CBAYCymaBay Therapeutics, Inc. | COM | 1,122,244 | $3.79M | 1.6% | +1,122,244 | New | History |
| RCKTRocket Pharmaceuticals, Inc. | COM | 165,000 | $3.60M | 1.5% | +84,772+105.7% | Added | History |
| CRISCuris Inc | COM NEW | 650,000 | $3.09M | 1.3% | +75,000+13.0% | Added | History |
| OBIOOrchestra BioMed Holdings, Inc. | ORD SHS | 300,000 | $3.00M | 1.3% | 00.0% | Unchanged | History |
| Environmental Impact Acqu Co29408N106 | COM CL A | 300,000 | $2.98M | 1.3% | 00.0% | Unchanged | – |
| MRTXMirati Therapeutics, Inc. | COM | 20,000 | $2.93M | 1.3% | −7,500−27.3% | Reduced | History |
| Medicus Sciences AcquisitionG5960S108 | CL A SHS | 300,000 | $2.92M | 1.2% | 00.0% | Unchanged | – |
| PRCTPROCEPT BioRobotics Corp | COM | 100,000 | $2.50M | 1.1% | +21,466+27.3% | Added | History |
| SNCEScience 37 Holdings, Inc. | COM | 150,000 | $1.87M | 0.8% | +150,000 | New | History |
| TVTXTravere Therapeutics, Inc. | COM | 50,000 | $1.55M | 0.7% | −150,000−75.0% | Reduced | History |
| Bio Green Med Solution, Inc.23254L603 | COM | 400,000 | $1.55M | 0.7% | 00.0% | Unchanged | – |
| NTLAIntellia Therapeutics, Inc. | COM | 10,000 | $1.18M | 0.5% | −5,000−33.3% | Reduced | History |
| RCORRenovacor, Inc. | COM | 125,000 | $963.0K | 0.4% | +10,000+8.7% | Added | History |
| Immatics N.V.N44445117 | *W EXP 07/01/202 | 190,000 | $834.0K | 0.4% | 00.0% | Unchanged | – |
| HYPRHyperfine, Inc. | COM CL A | 76,162 | $552.0K | 0.2% | +76,162 | New | History |
| LIANYLianBio | SPONSORED ADS | 72,406 | $446.0K | 0.2% | +72,406 | New | History |
| ALDXAldeyra Therapeutics, Inc. | COM | 100,759 | $403.0K | 0.2% | −97,000−49.0% | Reduced | History |
| IOVAIovance Biotherapeutics, Inc. | COM | 20,000 | $382.0K | 0.2% | −130,000−86.7% | Reduced | History |
| Renovacor, Inc.75989E114 | *W EXP 99/99/999 | 75,000 | $43.0K | <0.1% | 00.0% | Unchanged | – |
| Medicus Sciences AcquisitionG5960S124 | *W EXP 02/12/202 | 33,333 | $24.0K | <0.1% | 00.0% | Unchanged | – |
Options (9)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| FLNAFilana Therapeutics, Inc. | COM | $15.3M | – |
| MRNAModerna, Inc. | Stock | $7.62M | – |
| NVAXNovavax Inc | COM NEW | $7.15M | – |
| CRISCuris Inc | COM NEW | – | $5.00M |
| Curevac N VN2451R105 | COM | – | $1.72M |
| ARK ETF Tr00214Q302 | GENOMIC REV ETF | – | $1.53M |
| SEERSeer, Inc. | COM CL A | – | $1.14M |
| INOInovio Pharmaceuticals, Inc. | COM NEW | – | $998.0K |
| RFLRafael Holdings, Inc. | COM CL B | $516.0K | – |
Sold out since Q3 2021 (30)
Positions held at the end of Q3 2021 that are gone from this filing.
| Security | Class | Shares in Q3 2021 | Value in Q3 2021 | % of portfolio in Q3 2021 | History |
|---|---|---|---|---|---|
| OCULOcular Therapeutix, Inc | COM | 750,000 | $7.50M | 3.0% | History |
| XLRNAcceleron Pharma Inc | COM | 35,350 | $6.08M | 2.4% | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 35,910 | $5.72M | 2.3% | History |
| NSTGNS Wind Down Co., Inc. | COM | 75,000 | $3.60M | 1.4% | History |
| Trillium Therapeutics Inc.89620X506 | COM NEW | 200,000 | $3.51M | 1.4% | – |
| Gossamer Bio, Inc.38341PAA0 | NOTE 5.000% 6/0 | – | $2.09M | 0.8% | – |
| HARPHarpoon Therapeutics, Inc. | COM | 250,000 | $1.98M | 0.8% | History |
| GBTGlobal Blood Therapeutics, Inc. | COM | 75,000 | $1.91M | 0.8% | History |
| UTHRUnited Therapeutics Corp | COM | 10,000 | $1.85M | 0.7% | History |
| AFIBAcutus Medical, Inc. | COM | 200,000 | $1.77M | 0.7% | History |
| HZNPHorizon Therapeutics Public Ltd Co | SHS | 15,000 | $1.64M | 0.7% | History |
| MREOMereo BioPharma Group plc | SPON ADS | 650,000 | $1.57M | 0.6% | History |
| BFLYButterfly Network, Inc. | COM CL A | 150,000 | $1.57M | 0.6% | History |
| SNCEScience 37 Holdings, Inc. | COM | 150,000 | $1.47M | 0.6% | History |
| SDGRSchrodinger, Inc. | COM | 25,000 | $1.37M | 0.5% | History |
| PCVXVaxcyte, Inc. | COM | 50,000 | $1.27M | 0.5% | History |
| ZYMEZymeworks Inc. | COM | 38,814 | $1.13M | 0.4% | History |
| CELLBruker Cellular Analysis, Inc. | COM | 55,000 | $1.08M | 0.4% | History |
| FOLDAmicus Therapeutics, Inc. | COM | 111,400 | $1.06M | 0.4% | History |
| LKFTLakefront Biotherapeutics NV | SPON ADR | 20,000 | $1.05M | 0.4% | History |
| BHVNBiohaven Ltd. | COM | 7,500 | $1.04M | 0.4% | History |
| LUNGPulmonx Corp | COM | 25,000 | $900.0K | 0.4% | History |
| Achilles Therapeutics PLC00449L102 | SPONSORED ADS | 100,000 | $779.0K | 0.3% | – |
| IPHAInnate Pharma SA | SPONSORED ADS | 125,000 | $771.0K | 0.3% | History |
| TNGXTango Therapeutics, Inc. | COM | 50,000 | $647.0K | 0.3% | History |
| CTMXCytomX Therapeutics, Inc. | COM | 125,000 | $636.0K | 0.3% | History |
| Beauty Health Co88331L116 | EQUITY WRT | 34,400 | $498.0K | 0.2% | – |
| KROSKeros Therapeutics, Inc. | COM | 12,500 | $495.0K | 0.2% | History |
| Aslan Pharmaceuticals Ltd04522R101 | ADS | 250,000 | $445.0K | 0.2% | – |
| CRVSCorvus Pharmaceuticals, Inc. | COM | 50,000 | $242.0K | 0.1% | History |